

Global Long-acting Insulin Glargine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/G9F8BBDB5017EN.html>

Date: November 2025

Pages: 115

Price: US\$ 3,480.00 (Single User License)

ID: G9F8BBDB5017EN

Abstracts

According to our (Global Info Research) latest study, the global Long-acting Insulin Glargine market size was valued at US\$ 8359 million in 2024 and is forecast to a readjusted size of USD 7139 million by 2031 with a CAGR of -2.3% during review period.

In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.

Long-acting insulin glargine is a modified form of human insulin designed to provide a prolonged and steady release of insulin over approximately 24 hours. It helps maintain basal insulin levels in patients with diabetes mellitus, reducing the risk of blood sugar fluctuations between meals and overnight. Its unique formulation allows for once-daily dosing with minimal peak activity.

This report is a detailed and comprehensive analysis for global Long-acting Insulin Glargine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Long-acting Insulin Glargine market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Long-acting Insulin Glargine market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Long-acting Insulin Glargine market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Long-acting Insulin Glargine market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Long-acting Insulin Glargine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Long-acting Insulin Glargine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Eli Lilly & Co, Biocron Biologics, Gan & Lee, Tonghua Dongbao, Biocare, United Laboratories, KALBE PHARMA, Swixx Biopharma, INFION PHARMA, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Long-acting Insulin Glargine market is split by Type and by Application. For the period

Global Long-acting Insulin Glargine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2...

2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Vial

Prefilled

Market segment by Application

Type 1 Diabetes

Type 2 Diabetes

Major players covered

Sanofi

Eli Lilly & Co

Biocon Biologics

Gan & Lee

Tonghua Dongbao

Biocare

United Laboratories

KALBE PHARMA

Swixx Biopharma

INFION PHARMA

Viartis

Wockhardt

Lupin Laboratories

Cipla

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Long-acting Insulin Glargine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Long-acting Insulin Glargine, with price, sales quantity, revenue, and global market share of Long-acting Insulin Glargine from 2020 to 2025.

Chapter 3, the Long-acting Insulin Glargine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Long-acting Insulin Glargine breakdown data are shown at the regional

level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025. and Long-acting Insulin Glargine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Insulin Glargine.

Chapter 14 and 15, to describe Long-acting Insulin Glargine sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Long-acting Insulin Glargine Consumption Value by Type: 2020 Versus 2024 Versus 2031
 - 1.3.2 Vial
 - 1.3.3 Prefilled
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Long-acting Insulin Glargine Consumption Value by Application: 2020 Versus 2024 Versus 2031
 - 1.4.2 Type 1 Diabetes
 - 1.4.3 Type 2 Diabetes
- 1.5 Global Long-acting Insulin Glargine Market Size & Forecast
 - 1.5.1 Global Long-acting Insulin Glargine Consumption Value (2020 & 2024 & 2031)
 - 1.5.2 Global Long-acting Insulin Glargine Sales Quantity (2020-2031)
 - 1.5.3 Global Long-acting Insulin Glargine Average Price (2020-2031)

2 MANUFACTURERS PROFILES

- 2.1 Sanofi
 - 2.1.1 Sanofi Details
 - 2.1.2 Sanofi Major Business
 - 2.1.3 Sanofi Long-acting Insulin Glargine Product and Services
 - 2.1.4 Sanofi Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.1.5 Sanofi Recent Developments/Updates
- 2.2 Eli Lilly & Co
 - 2.2.1 Eli Lilly & Co Details
 - 2.2.2 Eli Lilly & Co Major Business
 - 2.2.3 Eli Lilly & Co Long-acting Insulin Glargine Product and Services
 - 2.2.4 Eli Lilly & Co Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.2.5 Eli Lilly & Co Recent Developments/Updates
- 2.3 Biocon Biologics
 - 2.3.1 Biocon Biologics Details

- 2.3.2 Biocon Biologics Major Business
- 2.3.3 Biocon Biologics Long-acting Insulin Glargine Product and Services
- 2.3.4 Biocon Biologics Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 Biocon Biologics Recent Developments/Updates
- 2.4 Gan & Lee
 - 2.4.1 Gan & Lee Details
 - 2.4.2 Gan & Lee Major Business
 - 2.4.3 Gan & Lee Long-acting Insulin Glargine Product and Services
 - 2.4.4 Gan & Lee Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.4.5 Gan & Lee Recent Developments/Updates
- 2.5 Tonghua Dongbao
 - 2.5.1 Tonghua Dongbao Details
 - 2.5.2 Tonghua Dongbao Major Business
 - 2.5.3 Tonghua Dongbao Long-acting Insulin Glargine Product and Services
 - 2.5.4 Tonghua Dongbao Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.5.5 Tonghua Dongbao Recent Developments/Updates
- 2.6 Biocare
 - 2.6.1 Biocare Details
 - 2.6.2 Biocare Major Business
 - 2.6.3 Biocare Long-acting Insulin Glargine Product and Services
 - 2.6.4 Biocare Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.6.5 Biocare Recent Developments/Updates
- 2.7 United Laboratories
 - 2.7.1 United Laboratories Details
 - 2.7.2 United Laboratories Major Business
 - 2.7.3 United Laboratories Long-acting Insulin Glargine Product and Services
 - 2.7.4 United Laboratories Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.7.5 United Laboratories Recent Developments/Updates
- 2.8 KALBE PHARMA
 - 2.8.1 KALBE PHARMA Details
 - 2.8.2 KALBE PHARMA Major Business
 - 2.8.3 KALBE PHARMA Long-acting Insulin Glargine Product and Services
 - 2.8.4 KALBE PHARMA Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)

- 2.8.5 KALBE PHARMA Recent Developments/Updates
- 2.9 Swixx Biopharma
 - 2.9.1 Swixx Biopharma Details
 - 2.9.2 Swixx Biopharma Major Business
 - 2.9.3 Swixx Biopharma Long-acting Insulin Glargine Product and Services
 - 2.9.4 Swixx Biopharma Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.9.5 Swixx Biopharma Recent Developments/Updates
- 2.10 INFION PHARMA
 - 2.10.1 INFION PHARMA Details
 - 2.10.2 INFION PHARMA Major Business
 - 2.10.3 INFION PHARMA Long-acting Insulin Glargine Product and Services
 - 2.10.4 INFION PHARMA Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.10.5 INFION PHARMA Recent Developments/Updates
- 2.11 Viatris
 - 2.11.1 Viatris Details
 - 2.11.2 Viatris Major Business
 - 2.11.3 Viatris Long-acting Insulin Glargine Product and Services
 - 2.11.4 Viatris Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.11.5 Viatris Recent Developments/Updates
- 2.12 Wockhardt
 - 2.12.1 Wockhardt Details
 - 2.12.2 Wockhardt Major Business
 - 2.12.3 Wockhardt Long-acting Insulin Glargine Product and Services
 - 2.12.4 Wockhardt Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.12.5 Wockhardt Recent Developments/Updates
- 2.13 Lupin Laboratories
 - 2.13.1 Lupin Laboratories Details
 - 2.13.2 Lupin Laboratories Major Business
 - 2.13.3 Lupin Laboratories Long-acting Insulin Glargine Product and Services
 - 2.13.4 Lupin Laboratories Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.13.5 Lupin Laboratories Recent Developments/Updates
- 2.14 Cipla
 - 2.14.1 Cipla Details
 - 2.14.2 Cipla Major Business

- 2.14.3 Cipla Long-acting Insulin Glargine Product and Services
- 2.14.4 Cipla Long-acting Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.14.5 Cipla Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: LONG-ACTING INSULIN GLARGINE BY MANUFACTURER

- 3.1 Global Long-acting Insulin Glargine Sales Quantity by Manufacturer (2020-2025)
- 3.2 Global Long-acting Insulin Glargine Revenue by Manufacturer (2020-2025)
- 3.3 Global Long-acting Insulin Glargine Average Price by Manufacturer (2020-2025)
- 3.4 Market Share Analysis (2024)
 - 3.4.1 Producer Shipments of Long-acting Insulin Glargine by Manufacturer Revenue (\$MM) and Market Share (%): 2024
 - 3.4.2 Top 3 Long-acting Insulin Glargine Manufacturer Market Share in 2024
 - 3.4.3 Top 6 Long-acting Insulin Glargine Manufacturer Market Share in 2024
- 3.5 Long-acting Insulin Glargine Market: Overall Company Footprint Analysis
 - 3.5.1 Long-acting Insulin Glargine Market: Region Footprint
 - 3.5.2 Long-acting Insulin Glargine Market: Company Product Type Footprint
 - 3.5.3 Long-acting Insulin Glargine Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Long-acting Insulin Glargine Market Size by Region
 - 4.1.1 Global Long-acting Insulin Glargine Sales Quantity by Region (2020-2031)
 - 4.1.2 Global Long-acting Insulin Glargine Consumption Value by Region (2020-2031)
 - 4.1.3 Global Long-acting Insulin Glargine Average Price by Region (2020-2031)
- 4.2 North America Long-acting Insulin Glargine Consumption Value (2020-2031)
- 4.3 Europe Long-acting Insulin Glargine Consumption Value (2020-2031)
- 4.4 Asia-Pacific Long-acting Insulin Glargine Consumption Value (2020-2031)
- 4.5 South America Long-acting Insulin Glargine Consumption Value (2020-2031)
- 4.6 Middle East & Africa Long-acting Insulin Glargine Consumption Value (2020-2031)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)
- 5.2 Global Long-acting Insulin Glargine Consumption Value by Type (2020-2031)

5.3 Global Long-acting Insulin Glargine Average Price by Type (2020-2031)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

6.2 Global Long-acting Insulin Glargine Consumption Value by Application (2020-2031)

6.3 Global Long-acting Insulin Glargine Average Price by Application (2020-2031)

7 NORTH AMERICA

7.1 North America Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)

7.2 North America Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

7.3 North America Long-acting Insulin Glargine Market Size by Country

7.3.1 North America Long-acting Insulin Glargine Sales Quantity by Country (2020-2031)

7.3.2 North America Long-acting Insulin Glargine Consumption Value by Country (2020-2031)

7.3.3 United States Market Size and Forecast (2020-2031)

7.3.4 Canada Market Size and Forecast (2020-2031)

7.3.5 Mexico Market Size and Forecast (2020-2031)

8 EUROPE

8.1 Europe Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)

8.2 Europe Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

8.3 Europe Long-acting Insulin Glargine Market Size by Country

8.3.1 Europe Long-acting Insulin Glargine Sales Quantity by Country (2020-2031)

8.3.2 Europe Long-acting Insulin Glargine Consumption Value by Country (2020-2031)

8.3.3 Germany Market Size and Forecast (2020-2031)

8.3.4 France Market Size and Forecast (2020-2031)

8.3.5 United Kingdom Market Size and Forecast (2020-2031)

8.3.6 Russia Market Size and Forecast (2020-2031)

8.3.7 Italy Market Size and Forecast (2020-2031)

9 ASIA-PACIFIC

9.1 Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)

9.2 Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

9.3 Asia-Pacific Long-acting Insulin Glargine Market Size by Region

9.3.1 Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Region (2020-2031)

9.3.2 Asia-Pacific Long-acting Insulin Glargine Consumption Value by Region (2020-2031)

9.3.3 China Market Size and Forecast (2020-2031)

9.3.4 Japan Market Size and Forecast (2020-2031)

9.3.5 South Korea Market Size and Forecast (2020-2031)

9.3.6 India Market Size and Forecast (2020-2031)

9.3.7 Southeast Asia Market Size and Forecast (2020-2031)

9.3.8 Australia Market Size and Forecast (2020-2031)

10 SOUTH AMERICA

10.1 South America Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)

10.2 South America Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

10.3 South America Long-acting Insulin Glargine Market Size by Country

10.3.1 South America Long-acting Insulin Glargine Sales Quantity by Country (2020-2031)

10.3.2 South America Long-acting Insulin Glargine Consumption Value by Country (2020-2031)

10.3.3 Brazil Market Size and Forecast (2020-2031)

10.3.4 Argentina Market Size and Forecast (2020-2031)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Type (2020-2031)

11.2 Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Application (2020-2031)

11.3 Middle East & Africa Long-acting Insulin Glargine Market Size by Country

11.3.1 Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Country (2020-2031)

11.3.2 Middle East & Africa Long-acting Insulin Glargine Consumption Value by Country (2020-2031)

11.3.3 Turkey Market Size and Forecast (2020-2031)

11.3.4 Egypt Market Size and Forecast (2020-2031)

11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)

11.3.6 South Africa Market Size and Forecast (2020-2031)

12 MARKET DYNAMICS

- 12.1 Long-acting Insulin Glargine Market Drivers
- 12.2 Long-acting Insulin Glargine Market Restraints
- 12.3 Long-acting Insulin Glargine Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Long-acting Insulin Glargine and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Long-acting Insulin Glargine
- 13.3 Long-acting Insulin Glargine Production Process
- 13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Long-acting Insulin Glargine Typical Distributors
- 14.3 Long-acting Insulin Glargine Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Long-acting Insulin Glargine Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Table 2. Global Long-acting Insulin Glargine Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Table 3. Sanofi Basic Information, Manufacturing Base and Competitors

Table 4. Sanofi Major Business

Table 5. Sanofi Long-acting Insulin Glargine Product and Services

Table 6. Sanofi Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 7. Sanofi Recent Developments/Updates

Table 8. Eli Lilly & Co Basic Information, Manufacturing Base and Competitors

Table 9. Eli Lilly & Co Major Business

Table 10. Eli Lilly & Co Long-acting Insulin Glargine Product and Services

Table 11. Eli Lilly & Co Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 12. Eli Lilly & Co Recent Developments/Updates

Table 13. Biocon Biologics Basic Information, Manufacturing Base and Competitors

Table 14. Biocon Biologics Major Business

Table 15. Biocon Biologics Long-acting Insulin Glargine Product and Services

Table 16. Biocon Biologics Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 17. Biocon Biologics Recent Developments/Updates

Table 18. Gan & Lee Basic Information, Manufacturing Base and Competitors

Table 19. Gan & Lee Major Business

Table 20. Gan & Lee Long-acting Insulin Glargine Product and Services

Table 21. Gan & Lee Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 22. Gan & Lee Recent Developments/Updates

Table 23. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors

Table 24. Tonghua Dongbao Major Business

Table 25. Tonghua Dongbao Long-acting Insulin Glargine Product and Services

Table 26. Tonghua Dongbao Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

- Table 27. Tonghua Dongbao Recent Developments/Updates
- Table 28. Biocare Basic Information, Manufacturing Base and Competitors
- Table 29. Biocare Major Business
- Table 30. Biocare Long-acting Insulin Glargine Product and Services
- Table 31. Biocare Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 32. Biocare Recent Developments/Updates
- Table 33. United Laboratories Basic Information, Manufacturing Base and Competitors
- Table 34. United Laboratories Major Business
- Table 35. United Laboratories Long-acting Insulin Glargine Product and Services
- Table 36. United Laboratories Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 37. United Laboratories Recent Developments/Updates
- Table 38. KALBE PHARMA Basic Information, Manufacturing Base and Competitors
- Table 39. KALBE PHARMA Major Business
- Table 40. KALBE PHARMA Long-acting Insulin Glargine Product and Services
- Table 41. KALBE PHARMA Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 42. KALBE PHARMA Recent Developments/Updates
- Table 43. Swixx Biopharma Basic Information, Manufacturing Base and Competitors
- Table 44. Swixx Biopharma Major Business
- Table 45. Swixx Biopharma Long-acting Insulin Glargine Product and Services
- Table 46. Swixx Biopharma Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 47. Swixx Biopharma Recent Developments/Updates
- Table 48. INFION PHARMA Basic Information, Manufacturing Base and Competitors
- Table 49. INFION PHARMA Major Business
- Table 50. INFION PHARMA Long-acting Insulin Glargine Product and Services
- Table 51. INFION PHARMA Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 52. INFION PHARMA Recent Developments/Updates
- Table 53. Viartis Basic Information, Manufacturing Base and Competitors
- Table 54. Viartis Major Business
- Table 55. Viartis Long-acting Insulin Glargine Product and Services
- Table 56. Viartis Long-acting Insulin Glargine Sales Quantity (K Units), Average Price

(US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 57. Viartis Recent Developments/Updates

Table 58. Wockhardt Basic Information, Manufacturing Base and Competitors

Table 59. Wockhardt Major Business

Table 60. Wockhardt Long-acting Insulin Glargine Product and Services

Table 61. Wockhardt Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 62. Wockhardt Recent Developments/Updates

Table 63. Lupin Laboratories Basic Information, Manufacturing Base and Competitors

Table 64. Lupin Laboratories Major Business

Table 65. Lupin Laboratories Long-acting Insulin Glargine Product and Services

Table 66. Lupin Laboratories Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 67. Lupin Laboratories Recent Developments/Updates

Table 68. Cipla Basic Information, Manufacturing Base and Competitors

Table 69. Cipla Major Business

Table 70. Cipla Long-acting Insulin Glargine Product and Services

Table 71. Cipla Long-acting Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 72. Cipla Recent Developments/Updates

Table 73. Global Long-acting Insulin Glargine Sales Quantity by Manufacturer (2020-2025) & (K Units)

Table 74. Global Long-acting Insulin Glargine Revenue by Manufacturer (2020-2025) & (USD Million)

Table 75. Global Long-acting Insulin Glargine Average Price by Manufacturer (2020-2025) & (US\$/Unit)

Table 76. Market Position of Manufacturers in Long-acting Insulin Glargine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 77. Head Office and Long-acting Insulin Glargine Production Site of Key Manufacturer

Table 78. Long-acting Insulin Glargine Market: Company Product Type Footprint

Table 79. Long-acting Insulin Glargine Market: Company Product Application Footprint

Table 80. Long-acting Insulin Glargine New Market Entrants and Barriers to Market Entry

Table 81. Long-acting Insulin Glargine Mergers, Acquisition, Agreements, and Collaborations

Table 82. Global Long-acting Insulin Glargine Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR

- Table 83. Global Long-acting Insulin Glargine Sales Quantity by Region (2020-2025) & (K Units)
- Table 84. Global Long-acting Insulin Glargine Sales Quantity by Region (2026-2031) & (K Units)
- Table 85. Global Long-acting Insulin Glargine Consumption Value by Region (2020-2025) & (USD Million)
- Table 86. Global Long-acting Insulin Glargine Consumption Value by Region (2026-2031) & (USD Million)
- Table 87. Global Long-acting Insulin Glargine Average Price by Region (2020-2025) & (US\$/Unit)
- Table 88. Global Long-acting Insulin Glargine Average Price by Region (2026-2031) & (US\$/Unit)
- Table 89. Global Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)
- Table 90. Global Long-acting Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)
- Table 91. Global Long-acting Insulin Glargine Consumption Value by Type (2020-2025) & (USD Million)
- Table 92. Global Long-acting Insulin Glargine Consumption Value by Type (2026-2031) & (USD Million)
- Table 93. Global Long-acting Insulin Glargine Average Price by Type (2020-2025) & (US\$/Unit)
- Table 94. Global Long-acting Insulin Glargine Average Price by Type (2026-2031) & (US\$/Unit)
- Table 95. Global Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)
- Table 96. Global Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)
- Table 97. Global Long-acting Insulin Glargine Consumption Value by Application (2020-2025) & (USD Million)
- Table 98. Global Long-acting Insulin Glargine Consumption Value by Application (2026-2031) & (USD Million)
- Table 99. Global Long-acting Insulin Glargine Average Price by Application (2020-2025) & (US\$/Unit)
- Table 100. Global Long-acting Insulin Glargine Average Price by Application (2026-2031) & (US\$/Unit)
- Table 101. North America Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)
- Table 102. North America Long-acting Insulin Glargine Sales Quantity by Type

(2026-2031) & (K Units)

Table 103. North America Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 104. North America Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 105. North America Long-acting Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 106. North America Long-acting Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 107. North America Long-acting Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 108. North America Long-acting Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 109. Europe Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 110. Europe Long-acting Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 111. Europe Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 112. Europe Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 113. Europe Long-acting Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 114. Europe Long-acting Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 115. Europe Long-acting Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 116. Europe Long-acting Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 117. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 118. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 119. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 120. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 121. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Region (2020-2025) & (K Units)

Table 122. Asia-Pacific Long-acting Insulin Glargine Sales Quantity by Region (2026-2031) & (K Units)

Table 123. Asia-Pacific Long-acting Insulin Glargine Consumption Value by Region (2020-2025) & (USD Million)

Table 124. Asia-Pacific Long-acting Insulin Glargine Consumption Value by Region (2026-2031) & (USD Million)

Table 125. South America Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 126. South America Long-acting Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 127. South America Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 128. South America Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 129. South America Long-acting Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 130. South America Long-acting Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 131. South America Long-acting Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 132. South America Long-acting Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 133. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 134. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 135. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 136. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 137. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 138. Middle East & Africa Long-acting Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 139. Middle East & Africa Long-acting Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 140. Middle East & Africa Long-acting Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 141. Long-acting Insulin Glargine Raw Material

Table 142. Key Manufacturers of Long-acting Insulin Glargine Raw Materials

Table 143. Long-acting Insulin Glargine Typical Distributors

Table 144. Long-acting Insulin Glargine Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Long-acting Insulin Glargine Picture

Figure 2. Global Long-acting Insulin Glargine Revenue by Type, (USD Million), 2020 & 2024 & 2031

Figure 3. Global Long-acting Insulin Glargine Revenue Market Share by Type in 2024

Figure 4. Vial Examples

Figure 5. Prefilled Examples

Figure 6. Global Long-acting Insulin Glargine Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Figure 7. Global Long-acting Insulin Glargine Revenue Market Share by Application in 2024

Figure 8. Type 1 Diabetes Examples

Figure 9. Type 2 Diabetes Examples

Figure 10. Global Long-acting Insulin Glargine Consumption Value, (USD Million): 2020 & 2024 & 2031

Figure 11. Global Long-acting Insulin Glargine Consumption Value and Forecast (2020-2031) & (USD Million)

Figure 12. Global Long-acting Insulin Glargine Sales Quantity (2020-2031) & (K Units)

Figure 13. Global Long-acting Insulin Glargine Price (2020-2031) & (US\$/Unit)

Figure 14. Global Long-acting Insulin Glargine Sales Quantity Market Share by Manufacturer in 2024

Figure 15. Global Long-acting Insulin Glargine Revenue Market Share by Manufacturer in 2024

Figure 16. Producer Shipments of Long-acting Insulin Glargine by Manufacturer Sales (\$MM) and Market Share (%): 2024

Figure 17. Top 3 Long-acting Insulin Glargine Manufacturer (Revenue) Market Share in 2024

Figure 18. Top 6 Long-acting Insulin Glargine Manufacturer (Revenue) Market Share in 2024

Figure 19. Global Long-acting Insulin Glargine Sales Quantity Market Share by Region (2020-2031)

Figure 20. Global Long-acting Insulin Glargine Consumption Value Market Share by Region (2020-2031)

Figure 21. North America Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 22. Europe Long-acting Insulin Glargine Consumption Value (2020-2031) &

(USD Million)

Figure 23. Asia-Pacific Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 24. South America Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 25. Middle East & Africa Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 26. Global Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 27. Global Long-acting Insulin Glargine Consumption Value Market Share by Type (2020-2031)

Figure 28. Global Long-acting Insulin Glargine Average Price by Type (2020-2031) & (US\$/Unit)

Figure 29. Global Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 30. Global Long-acting Insulin Glargine Revenue Market Share by Application (2020-2031)

Figure 31. Global Long-acting Insulin Glargine Average Price by Application (2020-2031) & (US\$/Unit)

Figure 32. North America Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 33. North America Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 34. North America Long-acting Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 35. North America Long-acting Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 36. United States Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 37. Canada Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 38. Mexico Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 39. Europe Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 40. Europe Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 41. Europe Long-acting Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 42. Europe Long-acting Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 43. Germany Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 44. France Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 45. United Kingdom Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 46. Russia Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 47. Italy Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 48. Asia-Pacific Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 49. Asia-Pacific Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 50. Asia-Pacific Long-acting Insulin Glargine Sales Quantity Market Share by Region (2020-2031)

Figure 51. Asia-Pacific Long-acting Insulin Glargine Consumption Value Market Share by Region (2020-2031)

Figure 52. China Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 53. Japan Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 54. South Korea Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 55. India Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 56. Southeast Asia Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 57. Australia Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 58. South America Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 59. South America Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 60. South America Long-acting Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 61. South America Long-acting Insulin Glargine Consumption Value Market

Share by Country (2020-2031)

Figure 62. Brazil Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 63. Argentina Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 64. Middle East & Africa Long-acting Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 65. Middle East & Africa Long-acting Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 66. Middle East & Africa Long-acting Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 67. Middle East & Africa Long-acting Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 68. Turkey Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 69. Egypt Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 70. Saudi Arabia Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 71. South Africa Long-acting Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 72. Long-acting Insulin Glargine Market Drivers

Figure 73. Long-acting Insulin Glargine Market Restraints

Figure 74. Long-acting Insulin Glargine Market Trends

Figure 75. Porters Five Forces Analysis

Figure 76. Manufacturing Cost Structure Analysis of Long-acting Insulin Glargine in 2024

Figure 77. Manufacturing Process Analysis of Long-acting Insulin Glargine

Figure 78. Long-acting Insulin Glargine Industrial Chain

Figure 79. Sales Channel: Direct to End-User vs Distributors

Figure 80. Direct Channel Pros & Cons

Figure 81. Indirect Channel Pros & Cons

Figure 82. Methodology

Figure 83. Research Process and Data Source

I would like to order

Product name: Global Long-acting Insulin Glargine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/G9F8BBDB5017EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9F8BBDB5017EN.html>